DUBLIN--(BUSINESS WIRE)--The "Metastatic Prostate Cancer (MPC) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The Metastatic Prostate Cancer (MPC) - Pipeline Insight, 2020 report provides comprehensive insights about 90+ companies and 110+ pipeline drugs in metastatic prostate cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
This report includes detailed analysis of various drugs in different stages of clinical development, including phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
There are approx. 90+ key companies which are developing the therapies for Metastatic Prostate Cancer. The companies which have their Metastatic Prostate Cancer drug candidates in the most advanced stage, i.e. Pre-registration phase include, Foresee Pharmaceuticals and Myovant Biosciences.
This report covers around 110+ products under different phases of clinical development like
- Late stage products (Pre-registration and Phase III)
- Mid-stage products (Phase II and Phase I/II) and
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intravenous
- Intradermal
- Intra-tumoral
- Oral
- Parenteral
- Subcutaneous etc.
- Mechanism of Action
Products have been categorized under various MOAs such as
- Luteinizing hormone-releasing hormone (LHRH) (GnRH) Agonists
- Luteinizing hormone-releasing hormone (LHRH) (GnRH) Agonists
- Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
- Vascular endothelial growth factor inhibitors
- Androgen receptor antagonists
- Cytotoxic T-lymphocyte antigen 4 inhibitors
- Programmed cell ligand 1 (PD-L1) Inhibitors
- Programmed cell ligand 1 (PD-L1) Inhibitors
- AKT inhibitors
- Polo like Kinase 1 (PLK1) inhibitor
- Adenosine A2A receptor antagonists
- SSRP1 protein inhibitors
- Cyclin-dependent kinase 4 inhibitors
- Indoleamine-pyrrole 2,3-dioxygenase inhibitors
- Cytochrome P 450 enzyme system inhibitors
- Glutamate carboxypeptidase II inhibitors
- Fibroblast growth factor receptor antagonists
- Transforming growth factor beta type I receptor antagonists
- HSP70 heat shock protein inhibitors
- Wnt signalling pathway modulators
- Stem cell markers suppression
- CD46 protein Inhibitors
- CD3 antigen inhibitors
- Tubulin inhibitors
- Calcitriol receptor agonists
- ROS1 protein inhibitors
- Insulin-like growth factor I inhibitors
- Insulin-like growth factor II inhibitors etc.
- Molecule Type
- Antibodies
- Cell Therapies Immunotherapies
- Liposome
- Microbiome
- Peptides
- Recombinant fusion proteins
- Small molecules
- Small interfering RNAs
- Vaccines
- Vitamin D analogues and others
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Prostate Cancer drugs.
Metastatic Prostate Cancer Report Insights
- Metastatic Prostate Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Metastatic Prostate Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Companies Mentioned
- Zenith Epigenetics
- WntResearch
- Veru Inc.
- VasGene Therapeutics
- ValiRx
- Vaccitech
- Ultimovacs ASA
- Trovagene
- Tracon
- Tmunity Therapeutics
- Tesaro
- Telix Pharmaceuticals
- Taiho Pharmaceutical
- Suzhou Kintor Pharmaceutical
- Sotio
- SeleXel
- Roche
- Regeneron Pharmaceuticals/Sanofi
- Progenics Pharmaceuticals, Inc.
- Poseida Therapeutics
- Pfizer Inc.
- Orion Corporation, Orion Pharma
- ORIC Pharmaceuticals
- OPKO Renal/Vifor Fresenius
- OncoMax
- Oncology Venture
- Novartis
- NewLink Genetics
- Nerviano Medical Sciences
- Nektar Therapeutics
- Myovant Biosciences
- Modra Pharmaceuticals
- Minneamrita Therapeutics
- Merck Sharp & Dohme Corp.
- Medivation
- MedImmune
- Madison Vaccines, Inc
- Laekna Therapeutics Shanghai Co. Ltd.
- Karyopharm Therapeutics
- Kangpu Biopharmaceuticals
- Jiangsu HengRui Medicine Co., Ltd.
- Janssen Research & Development, LLC
- Inovio Pharmaceuticals
- Innocrin Pharmaceutical
- Inhibitor Therapeutics, Inc.
- Immunomedics
- Hinova Pharmaceuticals USA, Inc.
- Harpoon Therapeutics
- Gilead
- Genzada Pharmaceuticals
- Genentech
- Fortis Therapeutics
- Foresee Pharmaceuticals
- Five Eleven Pharma
- ESSA Pharma
- Epizyme Inc.
- Eli Lilly and Company
- Effector Therapeutics
- DexTech Medical
- Corcept Therapeutics
- Constellation Pharmaceuticals
- Cleveland BioLabs
- CellCentric
- Celgene
- Cancer Targeted Technology
- Bristol Myers Squibb
- Boehringer Ingelheim
- BioNTech SE
- Bellicum Pharmaceuticals
- Beigene
- Bayer
- Bavarian Nordic
- AstraZeneca plc
- Astellas Pharmaceuticals/AstraZeneca
- Astellas Pharma Inc|Pfizer
- Arvinas Inc.
- Arcus Biosciences
- Aptevo Therapeutics
- Antigen Express
- Amgen
- Advaxis
- Advanced Accelerator Applications (A Novartis Company)
- Abbvie
- AB Science
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/76p26x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
